Gsa Capital Partners LLP Kinnate Biopharma Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$2.24 - $2.66 $9,614 - $11,416	-4,292 Reduced 1.27%	334,694 $890,000
Q4 2023 Feb 16, 2024	SELL	$1.07 - $2.5 $37,776 - $88,262	-35,305 Reduced 9.43%	338,986 $803,000
Q3 2023 Nov 15, 2023	BUY	$1.38 - $3.31 $184,848 - $443,367	133,948 Added 55.73%	374,291 $524,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $473,502 - $1.39 Million	203,220 Added 547.42%	240,343 $728,000
Q1 2023 May 12, 2023	SELL	$3.46 - $7.98 $114,356 - $263,746	-33,051 Reduced 47.1%	37,123 $232,000
Q4 2022 Feb 13, 2023	SELL	$5.26 - $12.19 $16,321 - $37,825	-3,103 Reduced 4.23%	70,174 $428,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $166,614 - $266,312	16,898 Added 29.97%	73,277 $876,000
Q2 2022 Aug 09, 2022	BUY	$7.43 - $13.0 $68,385 - $119,652	9,204 Added 19.51%	56,379 $711,000
Q1 2022 May 11, 2022	BUY	$7.73 - $17.99 $364,662 - $848,678	47,175 New	47,175 $531,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.